This conversion in the TGFβ function is known as the “TGFβ paradox” [71] and underlies the adverse prognosis that is associated with tumor growth, epithelial to mesenchymal transition (EMT) and invasion, evasion of immune surveillance, cancer cell dissemination and metastasis, as well as chemoresistance development. This evidence concerns the gene TGFB1 and cancer.